Cumberland Pharmaceuticals, Inc.

Cumberland Pharmaceuticals, Inc.

Cumberland Pharmaceuticals, Inc.

Overview
Date Founded

1999

Headquarters

2525 West End Avenue, Suite 950, Nashville, TN, 37203, USA

Type of Company

Public

Employees (Worldwide)

84

Industries

Pharmaceuticals
Retail: Drug Stores

Company Description

Cumberland Pharmaceuticals, Inc. is a pharmaceutical company, which engages in the acquisition, development, and commercialization of brands for the hospital acute care, gastroenterology, and oncology. Its product brands include acetadote, caldolor, kristalose, hepatoren, omeclamox, vaprisol, boxaban, vasculan, ethyol, portaban, and totect. The company was founded by A. J. Kazimi on January 6, 1999 and is headquartered in Nashville, TN.

Contact Data
Trying to get in touch with decision makers at Cumberland Pharmaceuticals, Inc.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Founder

Director, Chief Commercial Officer & Senior Vice President

Senior Vice President & Chief Compliance Officer

Senior Director, Field Sales & Marketing

Senior Director, Organizational Development

Senior Director, International Business

Senior Director, Accounting & Finance, Chief Financial Officer & Principal Accounting Officer

Director, Hospital Products

Executive Vice President, Operations & Chief Development Officer

Director, Senior Vice President & Medical Director

Board of Directors

Founder at Cumberland Pharmaceuticals, Inc.

Founder at Berkshire Asset Management LLC

Former President, New York at RCA Records

Senior Associate Dean, Clinical Sciences at Vanderbilt University

President & Chief Executive Officer at Behavioral Centers of America LLC

Director, Chief Commercial Officer & Senior Vice President at Cumberland Pharmaceuticals, Inc.

Former Managing Partner at KPMG LLP

Chief Executive Officer at Griggs & Associates

President at NashvilleHealth

Paths to Cumberland Pharmaceuticals, Inc.
Potential Connections via
Relationship Science
You
Cumberland Pharmaceuticals, Inc.
Owners & Shareholders
Details Hidden

Stonepine Capital Management focuses primarily, but not exclusively, on equity and equity-related securities in US publicly healthcare companies. The firm seeks to invest in companies whose valuations reflect a material discount to their fundamental value in the healthcare space. Stonepine typically prefers to invest in companies at a price reflecting a discount to current commercial and financial assets alone.The Stonepine Funds' investment objective is to achieve superior absolute returns while preserving capital. They have formed Special Purpose Vehicles (SPVs) whose investment objective may differ because these investments tend to be more concentrated than the Stonepine Funds. Stonepine seeks to achieve their investment objective primarily by investing assets in publicly traded healthcare companies. Stonepine's investment focus is companies with commercial stage products generating sustainable revenue and companies with substantial financial assets (such as cash and royalty income streams).

Details Hidden

Stonepine Capital Management focuses primarily, but not exclusively, on equity and equity-related securities in US publicly healthcare companies. The firm seeks to invest in companies whose valuations reflect a material discount to their fundamental value in the healthcare space. Stonepine typically prefers to invest in companies at a price reflecting a discount to current commercial and financial assets alone.The Stonepine Funds' investment objective is to achieve superior absolute returns while preserving capital. They have formed Special Purpose Vehicles (SPVs) whose investment objective may differ because these investments tend to be more concentrated than the Stonepine Funds. Stonepine seeks to achieve their investment objective primarily by investing assets in publicly traded healthcare companies. Stonepine's investment focus is companies with commercial stage products generating sustainable revenue and companies with substantial financial assets (such as cash and royalty income streams).

Recent Transactions
Details Hidden

Cumberland Pharmaceuticals, Inc. purchases Theravance Biopharma, Inc. /Vibativ from Theravance Biopharma, Inc.

Details Hidden

Cumberland Pharmaceuticals, Inc. purchases Astellas Pharma US, Inc. /Vaprisol from Astellas Pharma, Inc.

Details Hidden

Cumberland Pharmaceuticals, Inc. issued Common Stock

Transaction Advisors
Underwriter

Advised onCumberland Pharmaceuticals, Inc. issued Common Stock

Auditor

Advised onCumberland Pharmaceuticals, Inc. issued Common Stock

Underwriter

Advised onCumberland Pharmaceuticals, Inc. issued Common Stock

Advisors & Consultants
Legal Advisor

Partner at Finnegan, Henderson, Farabow, Garrett & Dunner LLP

Clients

CSL Ltd. is a biopharmaceutical company, which engages in the research, development, manufacture, marketing and distribution of biopharmaceutical and allied products. It operates through the CSL Behring and Seqirus segments. The CSL Behring segment provides plasma-derived and recombinant products, and operates plasma collection networks through CSL Plasma. The Seqirus segment manufactures and distributes non-plasma biotherapeutic products and develops influenza related products. The company was founded on November 2, 1961 and is headquartered in Parkville, Australia.

Fresenius SE & Co. KGaA is a global healthcare group, which engages in the provision of products, and services for dialysis, hospitals, and outpatient medical care. It operates through the following business segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, Fresenius Vamed, and Corporate & Other. The Fresenius Medical Care segment is comprised of dialysis products, and healthcare services. The Fresenius Kabi segment provides intravenous drugs, clinical nutrition, infusion therapy, medical devices, and transfusion technology. The Fresenius Helios is the hospital operations. The Fresenius Vamed is consist of projects, and services for hospitals and other healthcare facilities. The Corporate & Other segment engages in the holding activities. The company was founded by Eduard Fresenius in October 1912 and is headquartered in Bad Homburg, Germany.

Grifols SA is a vertically integrated global producer of plasma derivatives. Its activities include sourcing raw material, manufacturing various plasma derivative products and selling and distributing final products to healthcare providers. The company operates through the following segments: Bioscience, Hospital, Diagnostic and Raw Materials. The Bioscience Segment includes all activities related with products deriving from human plasma for therapeutic use. The Hospital Segment comprises of all non-biological pharmaceutical products and medical supplies manufactured by group companies earmarked for hospital pharmacy. The Diagnostic Segment includes the marketing of diagnostic testing equipment, reagents, and other equipment. The Raw Materials Segment includes the sale of intermediate biological products and the rendering of manufacturing services to third party companies. Grifols was founded by José Antonio Grifols Roig on November 18, 1940 and is headquartered in Barcelona, Spain.

Key Stats and Financials As of 2017
Market Capitalization
$84.5M
Total Enterprise Value
$76.6M
Earnings Per Share
$-0.5
Revenue
$41.2M
Net Profit
$-7.98M
EBITDA
$-1.43M
EBITDAMargin
-3.48%
Total Debt
$9.8M
Total Equity
$63.9M
Enterprise Value Sales
1.86x
TEVNet Income
-9.6x
Debt TEV
0.13x
Three Year Compounded Annual Growth Rate Of Revenue
3.7%
Five Year Compounded Annual Growth Rate Of Revenue
-3.37%
Investors
Details Hidden

Greer Capital Advisors invests in privately-held companies in the pharmaceutical, biotechnology, medical devices and diagnostics industries. They also invest in select healthcare services companies with a technology concentration or that are in a highly specialized market niche. Investments range from $100,000 to $2 million. They make investments with an average holding period of 2 to 4 years.Greer Capital Advisors looks for a proprietary technologies or products that originate from an academic research institution in Alabama. They also look for companies with a patent or patent pending technology, an experienced management team, technical and strategic leadership, industry transforming business models, existing or emerging revenue platforms and the potential to gain a significant share of a large or rapidly growing market. The firm focuses on investments in the Southeastern US.

Details Hidden

Cato BioVentures focuses on early-stage investment opportunities in private companies and PIPE opportunities in undervalued public companies in the life sciences sector. They target innovative therapeutics, medical devices, diagnostics and platform tools and technologies for improved drug discovery and development. Cato BioVentures seeks companies with novel therapeutics for central and peripheral nervous system disorders, cardiovascular disease, metabolic disease and cancer, with special emphasis on next generation embryonic stem cell-based technologies and skin penetration enhancement delivery systems. Cato BioVentures also seeks product development opportunities in public companies that have gone off track or fallen out of favor with the investment community. The firm's strategic services often serve as a bridge during the period between a company's formation or initial angel financing and its first institutional financing.Cato BioVentures often co-invests with other institutional investors and they generally do not require a board seat as a condition of their investment. In a board-like manner, the firm's principals regularly provide essential market, regulatory and drug development insights, as well as financial, operational and strategic advice.Cato seeks to invest in companies with a realistic business model built on reasonable assumptions, innovative drug candidates or technologies supported by a strong intellectual property position and a solid pathway to commercial protection. They prefer companies targeting a large market potential (at least $100 million in annual sales) within a reasonable amount of time (up to seven years) based upon a realistic analysis of the market from the bottom up.

Suppliers
Cardinal Health, Inc. Pharmaceuticals | DUBLIN, OH

Cardinal Health, Inc. engages in the provision of pharmaceutical and medical products. It operates through the Pharmaceutical and Medical segments. The Pharmaceutical segment distributes branded and generic pharmaceutical, specialty pharmaceutical, and over-the-counter healthcare and consumer products in the United States. The Medical segment manufactures, sources and distributes Cardinal Health branded medical, surgical and laboratory products, which are sold in the United States, Canada, Europe, Asia and other markets. The company was founded by Robert D. Walter in 1971 and is headquartered in Dublin, OH.

Vanderbilt University Schools & Student Services | Nashville, TN

and Form 990, Part III, Line 1, Description of Organization Mission:Vanderbilt University is a center for scholarly research, informed and creative teaching, and service to the community and society at large. Vanderbilt will uphold the highest standards and be a leader in the quest for new knowledge through scholarship, dissemination of knowledge through teaching and outreach, and creative experimentation of ideas and concepts. In pursuit of these goals, Vanderbilt values most highly the intellectual freedom that supports open inquiry and equality, compassion and excellence in all endeavors.

Clinigen Group Plc Commercial Scientific Research | Burton-on-Trent, SF

Clinigen Group Plc engages in the provision of pharmaceutical products and services. It operates through the following segments: Commercial Medicines, Unlicensed Medicines, and Clinical Trial Services. The Commercial Medicines segment acquires rights to niche hospital-only and critical care products and also provides access to licensed and branded generic. The Unlicensed Medicines segment supplies unlicensed medicines to hospital pharmacists and physicians for patients with a high unmet medical need. The Clinical Trial Services offers comparator medicines and services to clinical trials and IITs. The company was founded by Andrew Leaver in June 2010 and is headquartered in Burton-on-Trent, the United Kingdom.

Competitors
Merck & Co., Inc. Pharmaceuticals - Kenilworth, NJ

Merck & Co., Inc. , d.b.a. Merck Sharp & Dohme, MSD outside the United States and Canada, is an American pharmaceutical company and is one of the largest pharmaceutical companies in the world.

Sun Pharmaceutical Industries Ltd. Pharmaceuticals - Mumbai, MA

Sun Pharmaceutical We are an international speciality pharma company, with a large presence in the US and India, and a footprint across 41 other markets. In the US, which is our largest market, we have built a strong pipeline of generics, directly and through our subsidiaries Caraco and Sun Pharmaceutical Inc. Taro adds strong dermatology range to this portfolio. In India and rest of the world markets, our brands are prescribed in chronic therapy areas like cardiology, psychiatry, neurology, diabetology, ophthalmology, orthopedics etc. We are market leaders in speciality therapy areas in India. We retain the drive for growth that marked our early days, when we had. begun in 1983 with just 5 products. Since then, we have crossed several milestones to emerge as a leading pharma company in India where we are the 5th largest by prescription sales, a rank that we have retained over a decade. (IMS ORG Stockist Audit, March. 2012) Since the mid- nineties, we have used a combination of growth and acquisition to drive growth. important acquisitions have included those of the US, detroit-based Caraco Parma Labs and a plant at Halol which now holds UKMHRA and USFDA approvals. The 2010 acquisition of Taro Pharmaceuticals doubles our US business and brings us strengths in dermatology and pediatrics

Mylan NV Pharmaceuticals - Hatfield, HD

Mylan NV is a pharmaceutical healthcare company. The firm engages in the development, license, manufacture, market and distribution of generic, branded generic and specialty pharmaceutical products. It operates through the following geographical segments: North America, Europe, Rest of World, and Corporate or Other. The North America segment develops, manufactures, sells, and distributes pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, nebulized and cream, or ointment form. The Europe segment operates through subsidiaries in Italy, Germany, the United Kingdom, and Spain. The Rest of World segment comprises of operations in Japan, Australia, China, Brazil, Russia, India, South Africa, Middle East and South East Asia. The Corporate or Other segment covers other expenses not directly attributable to the segments and certain intercompany transactions of the firm. The company was founded in 1961 and is headquartered in Hatfield, the United Kingdom.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Cumberland Pharmaceuticals, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Cumberland Pharmaceuticals, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Cumberland Pharmaceuticals, Inc..
  • be_ixf; php_sdk; php_sdk_1.4.15
  • https://relationshipscience.com/organization/cumberland-pharmaceuticals-inc-130058
  • https://relationshipscience.com/organization/cumberland-pharmaceuticals-inc-130058